Profusa, Inc. Common Stock
Profusa, Inc. develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor gluco… Read more
Profusa, Inc. Common Stock (PFSA) - Total Liabilities
Latest total liabilities as of September 2025: $38.21 Million USD
Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has total liabilities worth $38.21 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Profusa, Inc. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Profusa, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Profusa, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Profusa, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tong Hua Holding Public Company Limited
BK:TH
|
Thailand | ฿32.56 Million |
|
Freightos Limited Warrants
NASDAQ:CRGOW
|
USA | $19.77 Million |
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
USA | $32.95 Million |
|
PARKER-HANNIFIN CO. - Dusseldorf Stock Exchang
DU:PAR
|
Germany | €16.70 Billion |
|
Equites Property Fund Ltd
JSE:EQU
|
South Africa | ZAC12.99 Billion |
|
Nureca Limited
NSE:NURECA
|
India | ₹259.46 Million |
|
Lipum AB
ST:LIPUM
|
Sweden | Skr11.63 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Profusa, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 8.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Profusa, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Profusa, Inc. Common Stock (2021–2024)
The table below shows the annual total liabilities of Profusa, Inc. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $122.28 Million | +9.29% |
| 2023-12-31 | $111.89 Million | +11.00% |
| 2022-12-31 | $100.80 Million | +6.09% |
| 2021-12-31 | $95.02 Million | -- |